| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Rifampicin 100mg/5mL syrup (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Rifampin 600mg injection+solvent |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Rifampicin 300mg injection+diluent (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Rifampicin+isoniazid 150mg/100mg tablet (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely isoniazid 150 milligram and rifampicin 300 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Streptomycin 1g injection (pdr for recon) (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely rifabutin 150 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely dapsone 50 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dapsone 100 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely clofazimine 100 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Nitrofurantoin 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely nitrofurantoin 100 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Nitrofurantoin 100mg m/r capsule (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Nitrofurantoin 25mg/5mL s/f suspension (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely nitrofurantoin 50 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Nitrofurantoin 100 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hexamine hippurate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hexamine hippurate 1g tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely nalidixic acid 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Nalidixic acid 60 mg/mL oral suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Nalidixic acid+sodium citrate 660mg/sachet effervescent granules |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Nalidixic acid 300mg/5mL s/f suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely ciprofloxacin 100 milligram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ciprofloxacin 50 mg/mL oral suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| ciprofloxacine 2 mg/mL, flacon de 200 mL pour perfusion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely ciprofloxacin 750 milligram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely ciprofloxacin 500 milligram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely ciprofloxacin 250 milligram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| ciprofloxacine 2 mg/mL, flacon de 50 mL pour perfusion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ciprofloxacin 200mg/100mL intravenous infusion (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ofloxacin 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ofloxacin 2mg/mL infusion solution 100mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ofloxacin 2mg/mL infusion solution 50mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ofloxacin 400 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Norfloxacin 400 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely levofloxacin 250 milligram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Levofloxacin 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Levofloxacin 5mg/mL infusion solution 100mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dapsone 100 mg and pyrimethamine 12.5 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely pyrimethamine 25 milligram and sulfadoxine 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Clindamycin 2% cream |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely sulfasalazine 500 milligram/1 each gastro-resistant oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Chloramphenicol 5 mg/mL eye drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Chloramphenicol 0.5% single-use eye drops (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely chloramphenicol 10 milligram/1 gram conventional release eye ointment (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Chloramphenicol eye drops (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely chlortetracycline hydrochloride 10 milligram/1 gram conventional release eye ointment (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Neomycin sulfate 5 mg/mL eye drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Neomycin sulfate 0.5% single-use eye drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Neomycin sulfate 5 mg/g eye ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Sulfacetamide sodium 10% eye drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Sulfacetamide 30% eye drops (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Sulfacetamide 20% eye drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Sulfacetamide 2.5% eye ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Sulfacetamide 6% eye ointment (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Sulfacetamide 10% eye ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Sulfacetamide eye drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ofloxacin 3 mg/mL eye drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ciprofloxacin (as ciprofloxacin hydrochloride) 3 mg/mL eye drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Lomefloxacin 0.3% eye drops (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Betamethasone sodium phosphate+neomycin sulfate 0.1/0.5% eye ointment (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Chloramphenicol 50 mg/mL ear drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely chloramphenicol 100 milligram/1 milliliter conventional release ear drops (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely gentamicin (as gentamicin sulfate) 3 milligram/1 milliliter and hydrocortisone acetate 10 milligram/1 milliliter conventional release ear drops (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Neomycin+hydrocortisone 0.5%/1.5% ear drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely neomycin sulfate 5 milligram/1 milliliter and prednisolone sodium phosphate 5 milligram/1 milliliter conventional release solution for ear or eye drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely hydrocortisone acetate 15 milligram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release ear and eye ointment (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely hydrocortisone acetate 15 milligram/1 milliliter and neomycin sulfate 5 milligram/1 milliliter conventional release solution for ear or eye drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Betamethasone (as betamethasone sodium phosphate) 1 mg/mL and neomycin sulfate 5 mg/mL ear and eye and nose drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely chlorhexidine hydrochloride 1 milligram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous cream (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely benzocaine 5 milligram and tyrothricin 1 milligram/1 each conventional release oromucosal lozenge (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone 10 mg/g and oxytetracycline (as oxytetracycline hydrochloride) 30 mg/g cutaneous ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone acetate 10 mg/g and neomycin sulfate 5 mg/g cutaneous cream |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Betamethasone+neomycin sulfate 0.1/0.5% ointment (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely betamethasone (as betamethasone valerate) 1 milligram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release cutaneous cream (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Tetracycline hydrochloride 2.2 mg/mL cutaneous solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Erythromycin 20 mg/mL cutaneous solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Erythromycin 40 mg/mL and zinc acetate 12 mg/mL cutaneous solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Erythromycin 3% in benzoyl peroxide topical gel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Erythromycin 20 mg/g cutaneous gel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Erythromycin 40 mg/g cutaneous gel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Erythromycin 40 mg/g and tretinoin 250 microgram/g cutaneous solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Clindamycin 1% roll-on lotion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Clindamycin 1% topical alcoholic solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely erythromycin 20 milligram/1 gram and isotretinoin 500 microgram/1 gram conventional release cutaneous gel (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Chloramphenicol DTF 1% cream |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Colistin sulfate topical powder |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Neomycin 0.5% cream BPC |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Silver sulfadiazine 1% cream (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Chlortetracycline hydrochloride 3% ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Amoxycillin trihydrate 200mg tablet disperdose for oral suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Amoxycillin trihydrate 400mg tablet disperdose for oral suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing monobactam (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Minocycline hydrochloride 1mg oral microspheres |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Amoxicillin 600mg tablet for oral suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Clindamycin phosphate 2% cream |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Clindamycin phosphate 20 mg/mL vaginal cream |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Daptomycin 250mg injection solution 10mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Daptomycin 500 mg injection solution 10 mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Moxifloxacin hydrochloride 0.5% ophthalmic solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely cefaclor 125 milligram/1 each conventional release chewable tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Bactericide |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.4-SNAPSHOT
|
FHIR Version n/a
User: [n/a]